XESP 8-K
Electronic Servitor Publication Network, Inc. (XESP)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 0R 15 (D) OF THE
SECURITIES EXCHANGE ACT OF 1934
September 23, 2020
Date of Report (Date of earliest event reported)
CANNASSIST INTERNATIONAL CORP.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 000-55740 | 82-1873116 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
1548 Loch Ness Dr.
Fallbrook, CA 92028
(Address of principal executive offices)
760-990-3091
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging Growth Company o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Securities registered pursuant to Section 12(b) of the Act: N/A
Item 7.01 Regulation FD Disclosure
On September 23, 2020, CannAssist International Corp. (the “Company”) issued a press release to announce that its common stock has been listed for trading on the OTCQB Venture Market under the symbol “CNSC.” The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The Company is furnishing the information under this Item 7.01 in this Current Report on Form 8-K to comply with Regulation FD. Such information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.
ITEM 9.01 Financial Statements and Exhibits
Exhibits
Certain exhibits listed below are incorporated by reference as so marked with the date and filing with which such exhibits were filed with the Securities and Exchange Commission.
| 99.1* | Press Release of CannAssist International Corp. dated September 23, 2020. |
| _____ | |
| * | Filed herewith |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: September 23, 2020
|
CANNASSIST INTERNATIONAL CORP.
| |
| By: /s/ Mark Palumbo | |
| Mark Palumbo | |
| Chief Executive Officer |
Exhibit 99.1
Unique Enhanced CBD Company - CANNASSIST INTL CORP. Commences Trading on the OTCQB under the Symbol: (CNSC)
FALLBROOK, CALIFORNIA (GLOBE NEWSWIRE) - CannAssist International Corporation (OTCQB: CNSC) (“Cannassist” or the “Company”) is pleased to announce the Company is now a new Publicly Traded Company on the OTC Markets Platform - OTCQB Markets Tier. The OTCQB requires a company to be fully reporting under SEC rules and guidelines as a means to promote transparency.
CEO/Founder Mark Palumbo stated. “Our Team has been working diligently for years to get to where we are now, third party testing has revealed that our proprietary process used in our products can facilitate enhanced absorbency of CBD and aid in promoting connections with the endocannabinoid receptors that exist within all humans. We are very excited to get to launch our new Enhanced CBD Product, “Xceptol” and assist as many as possible.”
About CannAssist INTL. Corp.
CannAssist produces and sells its cannabidiol ("CBD") product, "Cibidinol," which is formulated based on a proprietary process developed by its founder Mark Palumbo. CBD is a non-psychoactive compound found in hemp. CannAssist's initial research and development work, aimed at enhancing the bioavailability of desired molecular structures, resulted in the creation of a line of CBD products, most notably its CBD product, Cibidinol. Cibidinol will be available in a line of consumable and topical products that the company believes will make enhanced CBD products more available and accessible to consumers.
The same products you love with a new name - Xceptol represents the next step for Xceptor Labs products.
Possessing a National Drug Code (NDC), the highest quality ingredients, and the game-changing CiBiDinol, Xceptol Pain Cream is a CBD product with industry defining reliability and compliance.
For further information regarding the Company, please contact us at:
Xceptor
855 South Mission Ave, Ste K #400
Fallbrook, CA 92028
Tel. (888)991-2196
www.xceptol.com